Accelerate Timeline to Start PhI: Phase Appropriate Development and Integrated Drug Product Supply

Thursday, October 8, 2026 12:00 PM to 12:25 PM · 25 min. (CET)
Manufacturing 5.0: Hall 10 - 10K69
Manufacturing 5.0
Manufacturing

Information

In the early phase of drug development for peptide APIs, speed to start Phase I is absolutely key. With our early phase development concept, including process and analytical development, we can strongly reduce the time to manufacturing Tox and first GMP material. Synchronized timelines and parallel workflows between drug substance and drug product within our PepCellerate™ platform allows to save time while reducing risks. A case study will be presented.

Corden Pharma International GmbH6F58CordenPharma is a CDMO partner supporting biotech and pharma innovators of complex modalities in the advancement of their drug development lifecycle, providing bespoke outsourcing services spanning the complete supply chain, from early clinical-phase development to commercialization. With scientific expertise and partnership at its core, we provide customers high-value, end-to-end services with strategic focus on Peptides, Oligonucleotides, customized Lipid Excipients, Lipid NanoParticles, sterile Injectables and the extensive supply of Small Molecules (Highly Potent and Regular Potency).